Protection from articular damage by passive or active anti-tumour necrosis factor (TNF)-α immunotherapy in human TNF-α transgenic mice depends on anti-TNF-α antibody levels

Clinical and Experimental Immunology

Volumn 172, Issue 1, 2013, Pages 54-62

  Semerano, L ^a,b   Biton, J ^a   Delavallee L ^a   Duvallet, E ^a   Assier, E ^a   Bessis, N ^a   Bernier, E ^c   Dhellin, O ^c   Grouard Vogel, G ^c   Boissier, M C ^a,b  

^a UNIVERSITÉ PARIS 13   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c Neovacs SA   (France)

Author keywords

Experimental arthritis; Infliximab; Rheumatoid arthritis; TNF transgenic mouse; Tumour necrosis factor alpha

Indexed keywords

INFLIXIMAB; PHOSPHATE BUFFERED SALINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; TUMOUR NECROSIS FACTOR ALPHA KINOID; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTHROPATHY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARTILAGE, ARTICULAR; DRUG COMBINATIONS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY, ACTIVE; MALE; MICE; MICE, TRANSGENIC; ROC CURVE; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 84874979868     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12040     Document Type: Article

References (22)

1. Breedveld FC, Combe B. Understanding emerging treatment paradigms in rheumatoid arthritis. Arthritis Res Ther 2011; 13 (Suppl. 1):S3.
2. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010; 11:180-210.
3. Gaujoux-Viala C, Mouterde G, Baillet A etal. Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI. Joint Bone Spine 2012; 79:149-155.
4. Hetland ML, Christensen IJ, Tarp U etal. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62:22-32.
5. Russell AS. Quality-of-life assessment in rheumatoid arthritis. Pharmacoeconomics 2008; 26:831-846.
6. Dupond JL. Fatigue in patients with rheumatic diseases. Joint Bone Spine 2011; 78:156-160.
7. Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009; 11 (Suppl. 1):S1.
8. Bartelds GM, Krieckaert CL, Nurmohamed MT etal. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305:1460-1468.
9. Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 2010; 12:217.
10. Bendtzen K. Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies? Arthritis Rheum 2011; 63:867-870.
11. Radstake TR, Svenson M, Eijsbouts AM etal. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009; 68:1739-1745.
12. Semerano L, Assier E, Delavallee L, Boissier MC. Kinoid of human tumor necrosis factor-alpha for rheumatoid arthritis. Expert Opin Biol Ther 2011; 11:545-550.
13. Biton J, Semerano L, Delavallee L etal. Interplay between TNF and regulatory T cells in a TNF-driven murine model of arthritis. J Immunol 2011; 186:3899-3910.
14. Le Buanec H, Delavallee L, Bessis N etal. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci USA 2006; 103:19442-19447.
15. Delavallee L, Le Buanec H, Bessis N etal. Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Ann Rheum Dis 2008; 67:1332-1338.
16. Delavallee L, Semerano L, Assier E etal. Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis. Arthritis Res Ther 2009; 11:R195.
17. Hayward MD, Jones BK, Saparov A etal. An extensive phenotypic characterization of the hTNFalpha transgenic mice. BMC Physiol 2007; 7:13.
18. Keffer J, Probert L, Cazlaris H etal. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10:4025-4031.
19. Clavel G, Marchiol-Fournigault C, Renault G, Boissier MC, Fradelizi D, Bessis N. Ultrasound and Doppler micro-imaging in a model of rheumatoid arthritis in mice. Ann Rheum Dis 2008; 67:1765-1772.
20. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990; 300:230-235.
21. European Medicines Agency. European Public Assessment Reports (EPARs) infliximab. 2005. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000240/WC500050885.pdf (accessed October 2012).
22. European Medicines Agency. European Public Assessment Reports (EPARs) adalimumab. 2004. Available at: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000481/WC500050867.pdf (accessed October 2012).